Elmace SRL
Elmace reported total assets of €3.11m at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Apr 2026).
The score of Elmace shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +16 % Total assets +1 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Elmace's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 24 Apr 2026
- Year ended 30 Sep 2024filed on 02 May 2025
- Year ended 30 Sep 2023filed on 12 Mar 2024
- Year ended 30 Sep 2022filed on 15 Mar 2023
- Year ended 30 Sep 2021filed on 31 Mar 2022
Elmace's financial analysis
- Solvency99.2%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Elmace
Elmace's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0837.978.941
- VAT number
- BE0837978941
- Peppol
- Registered · 0208:0837978941 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Jul 2011
- Registered office
- 9880 Aalter
- Latest accounts
- 2025 · filed on 24 Apr 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Elmace (SRL) has been based in Aalter since 2011, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 510,655 € and equity of €3.08m; its revenue is not published. Its solvency stands at 99.2%, above the median of its sector (60.4%).
Companies similar to Elmace
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Dr. J. Bellon Research and experimental development on natural sciences and engineering Buggenhout · balance sheet €3.14m
- Pacira Belgium Research and experimental development on natural sciences and engineering Eupen · balance sheet €3.00m
- Montis Biosciences Research and experimental development on natural sciences and engineering Leuven · balance sheet €2.97m
- ImmuneSpec Research and experimental development on natural sciences and engineering Niel · balance sheet €3.54m
- K5 Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €3.56m
- Envitec Measurements AND Analytics SA Research and experimental development on natural sciences and engineering Gembloux · balance sheet €3.64m
- HepaVue Dx Research and experimental development on natural sciences and engineering Waterloo · balance sheet €3.71m
Frequently asked questions about Elmace
What is the revenue of Elmace?
Elmace files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Elmace?
In Belgium, the VAT number is the company number prefixed with BE: BE0837978941 for Elmace, if the company is VAT-registered. Its company number (CBE) is 0837.978.941.
Where is the registered office of Elmace?
According to the CBE register, the registered office of Elmace is in 9880 Aalter.
What is the equity of Elmace?
At the close of the 2025 financial year, the equity of Elmace amounts to 3,082,838 €, a solvency of 99.2% of total assets.
Who manages Elmace?
The register lists 1 active mandates at Elmace. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Elmace
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →